SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.04 EUR | 0.00% |
|
-0.72% | -3.24% |
| Jul. 11 | Medios to Join Germany's SDAX Index Amid Synlab's Delisting | MT |
| Jul. 10 | INDEX-MONITOR: Medios replaces Synlab in the SDax | DP |
| Sales 2024 * | 2.86B 3.12B | Sales 2025 * | 3.02B 3.3B | Capitalization | 2.43B 2.65B |
|---|---|---|---|---|---|
| Net income 2024 * | 81M 88.33M | Net income 2025 * | 67M 73.07M | EV / Sales 2024 * | 1.36 x |
| Net Debt 2024 * | 1.47B 1.6B | Net Debt 2025 * | 1.64B 1.79B | EV / Sales 2025 * | 1.35 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
36.9
x | Employees | 27,000 |
| Yield 2024 * |
1.85% | Yield 2025 * |
1.85% | Free-Float | 14.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
More press releases
| 1 week | -0.72% | ||
| Current month | -1.08% | ||
| 1 month | -0.36% | ||
| 3 months | +1.10% | ||
| 6 months | -5.88% | ||
| Current year | -3.24% |
1 week
11.04
11.08
1 month
11.0011.38
Current year
10.0012.30
1 year
8.0212.30
3 years
6.6924.60
5 years
6.6924.60
10 years
6.6924.60
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 57 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Marc Welters
BRD | Director/Board Member | - | 21-04-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 11.04 | 0.00% | 0 |
| 24-07-11 | 11.04 | -0.18% | 400 |
| 24-07-10 | 11.06 | +0.18% | 0 |
| 24-07-09 | 11.04 | -0.36% | 0 |
| 24-07-08 | 11.08 | -0.36% | 0 |
Delayed Quote Deutsche Boerse AG, July 12, 2024 at 02:01 am EDT
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-08-07
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
11.06
EUR
Average target price
14.5
EUR
Spread / Average Target
+31.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.02% | 8.58B | |
| +76.62% | 4.54B | |
| +14.48% | 2.94B | |
| -8.59% | 1.89B | |
| -53.65% | 1.86B | |
| -13.64% | 1.56B | |
| +22.37% | 1.26B | |
| -46.33% | 1.09B | |
| +16.04% | 963M |
- Stock Market
- Equities
- SYAB Stock
- SYAB Stock
